Scientists hunt for clues to predict CAR-T success in tough lymphoma
NCT ID NCT07236203
First seen Nov 19, 2025 · Last updated Apr 29, 2026 · Updated 17 times
Summary
This study aims to find out what factors help predict whether CAR-T therapy will work for people with relapsed or refractory large B-cell lymphoma. Researchers will look at patient health records, tumor features, and immune system changes in 80 participants. The goal is to better understand who benefits most from this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200231, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.